Latest Conference Articles

Ellyn Matthews Addresses Misconceptions About Sleep Disturbances

Ellyn Matthews, PhD, RN, AOCNS, CBSM, who holds the Elizabeth Stanley Cooper Endowed Chair in Oncology Nursing at the University of Arkansas for Medical Sciences, addresses common misconceptions that patients with cancer have about sleep disturbances.

Jeannine Brant on the Benefits of Patient-Reported Outcomes

Jeannine Brant, PhD, Billings Clinic, discusses the benefits of patient-reported outcomes in cancer care.

Adapt Healthcare Skills to Meet Cancer Needs of LGBT Community

Cancer doesn’t discriminate, but that doesn’t mean the healthcare system won’t. This proves to be even more true for the lesbian, gay, bisexual and transgender community.

Lynne Malestic Named CURE's 2016 Extraordinary Healer During 10th Annual Award Celebration

Lots of people take their work home with them, but Lynne Malestic, RN, has given the idea new meaning.

Carmela Hoefling Discusses Effects of Malnutrition During Surgery

Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.

Joel Stettler on Procedures for Fall-Risk Patients

Joel Stettler, BSN, RN, OCN, Moffitt Cancer Center, discusses procedures implemented at his institution for patients who are at risk for falls. 

Moving Proactively to Support Patients With EGFR Inhibitor-Related Dermatologic AEs

Developing a skin rash as a result of EGFR-inhibitor targeted therapy often signals that the drug is working, but for patients who experience these serious dermatologic adverse events, it may become so intolerable that they will scale back or even discontinue anticancer medications that could prolong their survival.

Phone Calls May Help Assess, Improve Oral Cancer Therapy Adherence

With the growing use of oral therapies in cancer care, it is crucial that oncology nurses are using a systematic approach to assess and improve adherence, according to Whitney Perry, APRN, AOCNP.

An Upstanding Role: How Nurses Can Help Prevent Patient Falls

The possibility that hospitalized cancer patients will fall is an ongoing concern among the medical professionals who care for them.

Darcy Burbage Discusses the Role of Nurses in Treating CIPN

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses the role nurses play in treating patients with chemotherapy-induced peripheral neuropathy (CIPN).

Dr. David Eagle on Cost-Drivers in Oncology

David Eagle, MD, past president of the Community Oncology Alliance (COA) and partner in Lake Norman Oncology, Mooresville, North Carolina, discuss controlling costs of cancer treatment.

Dr. Geschwind on Locoregional Therapy for Patients With Liver Cancer

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

Novel Agents on Horizon for Advanced HCC

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.

Immunotherapy Doubts Fading in GI Cancers

Immunotherapy approaches are showing early signs of activity against a range of gastrointestinal cancers, defying the skeptical view that these tumors would not respond to the emerging agents succeeding in other malignancies.

Dr. Douglas Evans on Neadjuvant Therapy for Pancreas Cancer

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

Multidisciplinary Treatment a Growing Need in Liver Cancer

Michael Choti, MD, explains the impact of advancements in the treatment of patients with liver cancer and how building on them will require all oncology professionals to work as a team.

Precision Medicine Vital to Value-Based GI Cancer Care

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

Numerous Frontline CRC Options Allow Individualized Approach

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

Dr. Bekaii-Saab on Active Agents for the Treatment of Colorectal Cancer

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Treating GI Cancers Is a “Team Sport,” Conference Leader Says

John L. Marshall, MD, discusses how the management of patients with gastrointestinal cancers requires a multidisciplinary approach.

Dr. Heery on Advancements in Treatment of Neuroendocrine Tumors

Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.

Entinostat/IL-2 Combination Active in Previously Untreated Renal Cell Carcinoma

More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

Dr. Ferris on CheckMate-141 Trial in Head and Neck Cancer

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).

Dr. Khleif on Next Steps to Take With Immunotherapy

Samir N. Khleif, MD, director, GRU Cancer Center, discusses next steps researchers and physicians need to take with immunotherapy in the field of oncology.

Using Multiple Biomarkers Improves Risk Prediction for Breast Cancer

The addition of three biological markers to conventional breast cancer risk models significantly improved the ability to distinguish women at high and low risk.

Frontline Pembrolizumab Induces Durable Responses in Merkel Cell Carcinoma

Anti–PD-1 therapy in the first-line induced responses in more than half of patients with advanced Merkel cell carcinoma, with encouraging durability to the responses.

Dr. Berger on Noninvasive Screening Tool for CRC

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).

Dr. DeMichele on the I-SPY2 Trial for HER2+ Breast Cancer

Angela M. DeMichele, MD, professor of Medicine and Epidemiology, University of Pennsylvania, discusses results of the HER2-positive breast cancer cohort of the phase II ISPY-2 trial, which investigated the neoadjuvant combinations of ado-trastuzumab emtansine (T-DM1) and pertuzumab (Perjeta) versus paclitaxel (Abraxane) and trastuzumab (Herceptin).

Nivolumab Doubles 1-Year OS Rates in Head and Neck Cancer

Treatment with single-agent nivolumab reduced the risk of death by 30% and double 1-year overall survival rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Dr. Fred Hirsch on Next Steps for Necitumumab in NSCLC

Fred R. Hirsch, MD, PhD, professor of medicine and pathology, University of Colorado Cancer Center, CEO, International Association for the Study of Lung Cancer (IASLC), discusses necitumumab for first-line treatment of advanced squamous non-small cell lung cancer (NSCLC).